Tharimmune Shares Surge 63.35% on Record Volume Spike Outpacing Previous Day by 869% to Rank 114th in Market Activity Amid Strategic Advances and Patent Wins

Tharimmune (THAR) surged 63.35% on August 25, 2025, with a trading volume of $610 million, a 869.1% increase from the prior day, ranking it 114th in market activity. The biotech firm has seen a series of strategic advancements, including securing global patents for its lead candidate, TH104, which targets chronic pruritus in primary biliary cholangitis and is being developed as a countermeasure against fentanyl-related respiratory depression. Recent FDA feedback has validated TH104’s potential, while positive clinical data on its metabolic profile and safety further bolster its therapeutic appeal.

The company has expanded its pipeline with TH023, an oral monoclonal antibody targeting tumor necrosis factor-alpha, which demonstrated favorable results in early trials. Tharimmune also announced the appointment of industry leaders, including Nancy Davis and James Gordon Liddy, to its board, enhancing its strategic direction. Collaborations, such as a partnership with Intract Pharma to develop an oral infliximab formulation, highlight its focus on innovative delivery methods for biologics.

A $5.47 million equity financing in Q2/Q3 2025 and a $1.74 million direct public offering in July 2025 underscore Tharimmune’s efforts to fund clinical development and regulatory milestones. Positive regulatory feedback from the EMA and the FDA for TH104’s chronic pruritus program, coupled with patent protections, strengthens its position in rare disease and national security applications.

A backtested strategy of holding top 500 high-volume stocks for one day from 2022 to 2025 yielded a 31.52% total return with a Sharpe ratio of 0.79. The approach generated a 0.98% average daily return, with peak and trough swings of 4.95% and -4.47%, reflecting market volatility and momentum-driven performance.